Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
- Conditions
- Epidermolytic IchthyosisPachyonychia CongenitaPalmoplantar Keratoderma
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 44
- Registration Number
- NCT06545695
- Locations
- 🇺🇸
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
- Conditions
- Pancreatic AdenocarcinomaMetastatic Pancreatic CancerBasal Cell Neoplasm
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 104
- Registration Number
- NCT06483555
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06161558
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
- Conditions
- Solid TumorsAdvanced Solid TumorsMetastatic Cancer
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT05904457
- Locations
- 🇰🇷
Cha University Bundang Medical Center, Seongnam, Gyeonggi-do, Korea, Republic of
🇰🇷Chungnam National University Hospital, Daejeon, Chungcheongnam-do, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5279
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
- Conditions
- LiposarcomaNon-small Cell Lung CancerBreast CancerBladder CancerNon-Small Cell Lung AdenocarcinomaEsophageal CancerGastric CancerNon-Small Cell Squamous Lung CancerHead and Neck Squamous Cell CarcinomaOvarian Cancer
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Boundless Bio
- Target Recruit Count
- 150
- Registration Number
- NCT05827614
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Sarcoma Oncology, Santa Monica, California, United States
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
- Conditions
- Solid TumorAdvanced Solid TumorMetastatic Cancer
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05525858
- Locations
- 🇰🇷
Soonchunhyang University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Chungju, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: 30 μg OBI-833/100 μg OBI-821
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05442060
- Locations
- 🇨🇳
National Taiwan University Cancer Center, Taipei, Da'an Dist., Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳Tri-Service General Hospital, Taipei, Neihu District, Taiwan
Brazilian Lung Immunotherapy Study
- Conditions
- Lung Neoplasm
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Hospital Israelita Albert Einstein
- Target Recruit Count
- 154
- Registration Number
- NCT05081674
- Locations
- 🇧🇷
Hospital Municipal Vila Santa Catarina, São Paulo, Brazil
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
- Conditions
- Sporadic Papillary Renal Cell CarcinomaStage IV Renal Cell Cancer AJCC v8Hereditary Leiomyomatosis and Renal Cell CarcinomaRenal Cell CarcinomaPapillary Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyProcedure: Computed Tomography with ContrastProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT04981509
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.